
Sign up to save your podcasts
Or


Josh Schimmer is the preeminent equity analyst in the biotech industry; he's seen the good, the bad, and the ugly. Join us as we dive deep into his experiences reviewing corporate decks, the consequence of a deck falling short and the missed opportunity for a relationship.
By Mighty Spark CommunicationsJosh Schimmer is the preeminent equity analyst in the biotech industry; he's seen the good, the bad, and the ugly. Join us as we dive deep into his experiences reviewing corporate decks, the consequence of a deck falling short and the missed opportunity for a relationship.